1887
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Direct detection of cancer biomarkers in blood using a “place n play” modular polydimethylsiloxane pump
Rent:
Rent this article for
USD
10.1063/1.4807803
/content/aip/journal/bmf/7/3/10.1063/1.4807803
http://aip.metastore.ingenta.com/content/aip/journal/bmf/7/3/10.1063/1.4807803
View: Figures

Figures

Image of FIG. 1.
FIG. 1.

Schematic diagram of the proposed microfluidic device: (a) Exploded view, (b) top view, (c) cross sections of plasma separation, and (d) illustration of experimental procedure for immunoassay based on gold nanoparticle silver enhancement.

Image of FIG. 2.
FIG. 2.

Schematic illustration of the operation of the proposed microfluidic device: (a) A PDMS stamp is sealed over a glass slide and capture antibodies are loaded into microchannels. (b) After incubation, the PDMS stamp is peeled off and the patterned lines of capture antibodies are produced on the surface of the glass substrate. (c) The substrate patterned with lines of capture antibodies is turned over and reversibly sealed over a molded PDMS-glass assembly, then aliquots of blood samples are dispensed into the inlet ports of the microchip and plasma separation and antigen/DP capture are performed by mounting a “PnP” PDMS pump on the microchip. (d) After antigen/DP capture, all channels are flushed with PBS to remove unbound DP, and then aliquots silver solution are loaded into channels for further signal enhancement.

Image of FIG. 3.
FIG. 3.

Self-extraction of plasma from whole blood using the proposed microfluidic device: (a) Effect of the degassed time of PDMS pump and the vacuum level on the plasma extraction from whole blood. Error bars are based on standard deviation with n = 3. (b) Fast and effective plasma separation of six separate whole-blood samples by gravity-driven blood cell sedimentation in the proposed microfluidic device.

Image of FIG. 4.
FIG. 4.

(a) Photograph of 13-nm AuNPs shown at the transmission electron microscopy image. (b) Image of the color change at AuNPs labeled with CEA antibody, the final concentration of antibody and NaCl in five tube (No. 1: 5 g/ml CEA, 2 mM NaCl; No. 2: 10 g/ml CEA, 2.5 mM NaCl; No. 3: 20 g/ml CEA, 3 mM NaCl; No. 4: 30 g/ml CEA, 3.5 mM NaCl; No. 5: 40 g/ml CEA, 4 mM NaCl). (c) Image of the color change at AuNPs labeled with CYFRA21-1 antibody, the final concentration of antibody and NaCl in five tube (No. 1: 30 g/ml CYF21-1, 3 mM NaCl; No. 2: 40 g/ml CYF21-1, 3.5 mM NaCl; No. 3:50 g/l CYF21-1, 4 mM NaCl; No. 4:55 g/ml CYF21-1, 4.5 mM NaCl; No. 5:60 g/ml CYF21-1, 5 mM NaCl). (d) UV-Vis spectra of AuNPs solution and coating with antibody.

Image of FIG. 5.
FIG. 5.

(a) Concentration optimization graph of DP1 (AuNPs labeled with CEA antibody). (b) Concentration optimization graph of DP2 (AuNPs labeled with CYFRA21-1 antibody). Error bars are based on standard deviation with n = 3.

Image of FIG. 6.
FIG. 6.

Whole blood sample-to-answer assay using the proposed microfluidic devices: (a) Images of silver-enhanced signals on detection sites coated with anti-CEA antibody, anti-CYFRA21-1 antibody, anti-goat IgG as a positive reference and BSA as a negative reference. No. 1: sample containing only CYFRA21-1 antigen, No. 2: sample containing only CEA antigen, No. 3: sample containing both CEA and CYFRA21-1 antigens, No. 4: negative sample (no antigen). (b) The optical density obtained for immunoassays done with the mixture of CEA and CYFRA21-1 on the proposed chip, while keeping the concentration of CYFRA21-1 in constant (5 ng/ml) and varying the concentration of CEA (50 pg/ml, 500 pg/ml, 2.5 ng/ml, 5 ng/ml, 10 ng/ml, and 15 ng/ml). (c) The optical density obtained for immunoassays done with the mixture of CEA and CYFRA21-1 on the proposed chip, while keeping the concentration of CEA in constant (5 ng/ml) and varying the concentration of CYFRA21-1 (60 pg/ml, 600 pg/ml, 3 ng/ml, 6 ng/ml, 12 ng/ml, and 18 ng/ml). Error bars are based on standard deviation with n = 3.

Loading

Article metrics loading...

/content/aip/journal/bmf/7/3/10.1063/1.4807803
2013-05-23
2014-04-24
Loading

Full text loading...

This is a required field
Please enter a valid email address
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd
Scitation: Direct detection of cancer biomarkers in blood using a “place n play” modular polydimethylsiloxane pump
http://aip.metastore.ingenta.com/content/aip/journal/bmf/7/3/10.1063/1.4807803
10.1063/1.4807803
SEARCH_EXPAND_ITEM